Agenus Inc (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies, announced yesterday that it has appointed I-O drug development experts to key leadership positions.
These appointments are intended to help advance multiple clinical programs and planned BLA filings by 2020.
The company has named Dr Sunil Gupta as its vice president of regulatory and pharmacovigilance. He is a trained oncologist with around 30 years in senior leadership positions in clinical development and regulatory affairs. He joins Agenus from Sanofi where he had a career for 22 years including leading the approvals of Cemiplimab (anti-PD-1), Iniparib (PARP inhibition), Oxaliplatin and Taxotere.
The firm has also appointed Dr Anna Wijatyk as its vice president of clinical development. She was earlier vice president oncology & global development lead in hematologic cancers at Shire. She is a clinician with more than 20 years of experience in leadership positions at Bristol-Myers Squibb, Baxter, and Shire in oncology and rare diseases, leading to approvals of products with the FDA, EMA and Health Canada.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial